Inmed pharmaceuticals announces granting of patent for novel compounds

Marks the first jurisdictional issuance of an international patent for a family of novel small molecule compounds patent covers novel analog compounds for therapeutic applications in pain, glaucoma, inflammatory disease, anxiety, and a variety of neurological conditions including parkinson's disease, alzheimer's disease and dementia patent also protects the methods of preparation of the compounds vancouver, british columbia--(newsfile corp. - january 22, 2025) - inmed pharmaceuticals inc. (nasdaq: inm) ("inmed" or the "company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, today announces it has been granted an international patent cooperation treaty ('pct') patent in the first of several jurisdictions where the patent has been filed. titled "cannabinoid analogs and methods for their preparation ", this patent protects the use of several proprietary small molecule compounds and methods of their preparation, including the drug candidates screened for inmed's alzheimer's disease and dry age-related macular degeneration programs.
INM Ratings Summary
INM Quant Ranking